9月5日，药明康德涨5.09%，截至发稿，报107.13元/股，成交78.76亿元，换手率3.05%，总市值3161.95 亿元。 长安沪深300非周期指数A（740101）基金经理为肖洁。 截至发稿，肖洁累计任职时间3年211天，现任基金资产总规模5.16亿元，任职期间最佳基金回报 27.32%， 任职期间最差基金回报-26.3%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，无锡药明康德新药开发股份有限公司位于上海浦东新区外高桥保税区富特中路288号,香港铜 锣湾希慎道33号利园1期19楼1910室，成立日期2000年12月1日，上市日期2018年5月8日，公司主营业务 涉及小分子化学药的发现、研发及生产全方位、一体化平台服务,以全产业链平台的形式面向全球制药 企业提供各类新药的研发、生产及配套服务。主营业务收入构成为：化学业务78.37%，测试业务 12.93%，生物学业务6.02%，其他(补充)1.90%，其他业务0.79%。 从 ...

Company Overview - WuXi AppTec, established on December 1, 2000, is located in Shanghai and Hong Kong, and was listed on May 8, 2018. The company provides a comprehensive platform for the discovery, development, and manufacturing of small molecule drugs, serving global pharmaceutical companies [1] - The company's revenue composition is as follows: Chemical business 78.37%, Testing business 12.93%, Biological business 6.02%, Other (supplementary) 1.90%, Other business 0.79% [1] Stock Performance - On September 4, WuXi AppTec's stock fell by 5.04%, trading at 105.29 CNY per share, with a total transaction volume of 4.619 billion CNY and a turnover rate of 1.74%. The total market capitalization is 310.764 billion CNY [1] Fund Holdings - TaiKang Fund has a significant position in WuXi AppTec, with its Medical Health fund (159760) reducing its holdings by 10,200 shares in the second quarter, now holding 121,100 shares, which constitutes 10.52% of the fund's net value, making it the largest holding [2] - The Medical Health fund was established on December 6, 2021, with a latest scale of 80.0606 million CNY. Year-to-date returns are 22.55%, ranking 1802 out of 4222 in its category, while the one-year return is 37.42%, ranking 2442 out of 3789 [2]

Core Viewpoint - The company, WuXi AppTec, is a leading global provider of integrated new drug research and production services, benefiting from the depreciation of the Renminbi and its strong position in the CRO and CMO sectors [2][3]. Company Overview - WuXi AppTec is an integrated platform for the discovery, development, and production of small molecule chemical drugs, serving global pharmaceutical companies [2][7]. - The company was established on December 1, 2000, and went public on May 8, 2018 [7]. - The revenue composition includes: Chemical business 78.37%, Testing business 12.93%, Biological business 6.02%, Other (supplement) 1.90%, Other business 0.79% [7]. Financial Performance - For the first half of 2025, WuXi AppTec achieved revenue of 20.799 billion yuan, a year-on-year increase of 20.64%, and a net profit attributable to shareholders of 8.561 billion yuan, up 101.92% year-on-year [7]. - The company has distributed a total of 13.027 billion yuan in dividends since its A-share listing, with 9.373 billion yuan distributed over the past three years [8]. Market Position - WuXi AppTec holds a dominant position in the domestic pharmaceutical outsourcing industry and is one of the earliest companies engaged in CRO and CMO services in China [2]. - As of the 2024 annual report, overseas revenue accounted for 78.67% of total revenue, benefiting from the depreciation of the Renminbi [3]. Shareholder Information - As of July 15, 2025, the number of shareholders is 235,500, with no change in the average circulating shares per person [7]. - Major shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable increases in holdings by some institutional investors [8][9].

Group 1 - The proposal regarding the cancellation of the supervisory board, changes to the company's registered capital, and amendments to the articles of association needs to be submitted to the company's second extraordinary general meeting of shareholders in 2025 for review [1] - The shareholders' meeting will authorize the board of directors to handle the changes to the registered capital and amendments to the articles of association, with further authorization to the chairman or other designated individuals for related business registration and filing matters [1] Group 2 - The announcement is made by the board of directors of Wuxi AppTec Co., Ltd. on September 3, 2025 [2]

Core Viewpoint - WuXi AppTec is restructuring its organization to clarify the roles and responsibilities of its domestic operating entities and holding platforms, which includes transferring 98.9% of the shares of Hualan Pharmaceutical held by its subsidiary Shanghai WuXi to a newly established wholly-owned subsidiary, WuXi Research [1][2] Group 1: Company Actions - The share transfer involves WuXi AppTec transferring its entire 98.9% stake in Hualan Pharmaceutical to WuXi Research, which will directly hold these shares post-transfer [1] - This share transfer is within the board's authority and does not require shareholder approval, nor does it constitute a related party transaction or a major asset restructuring as per regulations [1] Group 2: Industry Context - The global CDMO industry is shifting from "capacity competition" to "technology + efficiency competition," with Hualan Pharmaceutical needing to adapt to technological advancements and evolving customer demands [2] - The restructuring aims to integrate resources between WuXi Research and Hualan Pharmaceutical, facilitating seamless transitions from research demands to production, which is crucial for maintaining Hualan's competitive edge in the small molecule sector [2] Group 3: Financial Implications - The share transfer is an internal asset reconfiguration that does not involve cash transactions, thus it will not significantly impact WuXi AppTec's financial statements [2] - The restructuring is expected to enhance overall operational efficiency in the long term, potentially leading to positive financial performance [2][3] Group 4: Future Considerations - The specific plan and implementation timeline for the share transfer remain uncertain, pending the signing of relevant agreements and approvals from tax authorities and business registration [3]

Core Viewpoint - WuXi AppTec is transferring 98.9% of its shares in Shanghai Hualian Pharmaceutical Co., Ltd. to WuXi AppTec (Shanghai) Pharmaceutical Development Co., Ltd. to optimize its organizational structure and enhance operational efficiency [1][3]. Company Summary - The share transfer is an internal asset reconfiguration and does not involve cash transactions, thus it will not significantly impact WuXi AppTec's financial statements [2]. - The transfer will not change the scope of consolidated financial statements or affect the operational activities of Hualian Pharmaceutical, nor will it impact its profits and overall equity [2]. - The restructuring aims to clarify the roles and responsibilities between domestic operating entities and holding platforms, enhancing the focus on core business areas [3]. Industry Summary - The global pharmaceutical CDMO industry is shifting from "capacity competition" to "technology + efficiency" competition, necessitating that Hualian Pharmaceutical adapt to technological advancements and evolving customer demands [1]. - The restructuring allows Hualian Pharmaceutical to concentrate on small molecule drug production processes, improving its professional capabilities while leveraging WuXi AppTec's global network to meet regional compliance and cost requirements [4]. - The specific implementation of the share transfer remains uncertain, pending the signing of relevant agreements and approvals from tax authorities and business registration [4].

Group 1 - The core point of the article is that WuXi AppTec announced the approval of several resolutions during its board meeting, including the cancellation of the supervisory board, changes to the company's registered capital, and amendments to the company's articles of association [2] Group 2 - The announcement was made on the evening of September 2, indicating a significant corporate governance change [2] - The resolutions will also involve the handling of business registration changes [2]

证券日报网讯 9月2日晚间，药明康德发布公告称，公司将于2025年9月23日召开2025年第二次临时股东 大会。本次股东大会将审议《关于取消监事会、变更公司注册资本、修改公司章程并办理工商变更登记 的议案》等多项议案。 （编辑 任世碧） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 李革博士 香港，2025年9月2日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 无锡药明康德新药开发股份有限公司 董事会议事规则 董事会议事规则 第一章 总则 第一条 为了进一步规范无锡药明康德新药开发股份有限公司（以下简称 "公司"）董事会（以下简称"董事会"）的议事方 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因依賴該等內容而引致之任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 茲載列本公司在上海證券交易所網站刊登的以下資料中文全文，僅供參閱。 承董事會命 無錫藥明康德新藥開發股份有限公司 董事長 （股份代號：2359） 海外監管公告 本海外監管公告乃由本公司根據香港聯合交易所有限公司證券上市規則第 13.10B條作出。 李革博士 香港，2025年9月2日 截至本公告日期，本公司董事會包括執行董事李革博士、陳民章博士、楊青博士及張朝暉先生； 非執行董事童小幪先生及吳亦兵博士；以及獨立非執行董事盧韶華女士、俞衛博士、張新博士、 詹智玲女士及冷雪松先生。 * 僅供識別 无锡药明康德新药开发股份有限公司 股东会议事规则 （2025 年修订） （於中華人民共和國註冊成立的股份有限公司） 无锡药明康德新药开发股份有限公司 股东会议事规则 第一章 总则 第一条 为进一步明确无锡药明康德新药开发股份有限公司（以 ...